Company TherapeuticsMD, Inc.

TXMD

US88338N2062

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.86 ^USD	-0.53%		0.00%	-17.33%

Mar. 29	TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 06	Knight Therapeutics Announces Launch of Bijuva in Canada	MT

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Number of employees: 1

USD in Million	2022	Weight	2023	Weight	Delta
License 100.0 %	70	100.0 %	1	100.0 %	-98.14%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	70	100.0 %	1	100.0 %	-98.14%

Managers	Title	Age	Since
Marlan Walker CEO	Chief Executive Officer	50	13-05-31
Joseph Ziegler DFI	Director of Finance/CFO	-	23-08-16
Douglas Mike Steelman PRN	Corporate Officer/Principal	-	18-02-28
C. Christine Miller LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Tommy Thompson CHM	Chairman	81	12-04-15
Cooper Collins BRD	Director/Board Member	45	12-02-27
Gail Naughton BRD	Director/Board Member	69	20-03-19
Justin Roberts BRD	Director/Board Member	-	22-08-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,532,443	11,096,283 ( 96.22 %)	0	96.22 %

Name	Equities	%	Valuation
Rubric Capital Management LP 11.27 %	1,192,191	11.27 %	3 M $
Clearline Capital LP 4.409 %	466,211	4.409 %	1 M $
Tejara Capital Ltd. 3.801 %	401,937	3.801 %	920 436 $
Vanguard Global Advisers LLC 3.665 %	387,582	3.665 %	887 563 $
Adar1 Capital Management LLC 2.574 %	272,160	2.574 %	623 246 $
BlackRock Institutional Trust Co. NA 1.277 %	134,998	1.277 %	309 145 $
Morgan Stanley Capital Services LLC 1.246 %	131,767	1.246 %	301 746 $
Hugh O'Dowd 1.150 %	121,666	1.150 %	278 615 $
Geode Capital Management LLC 0.8018 %	84,788	0.8018 %	194 165 $
Brian Bernick 0.6149 %	65,026	0.6149 %	148 910 $

TherapeuticsMD, Inc.

951 Yamato Road Suite 220

33431, Boca Raton

+561 961 1900

http://www.therapeuticsmd.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
THERAPEUTICSMD, INC.	-17.33%	21.45M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals